Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial).

MLA

Sato, Yoshiaki, et al. “Safety and Tolerability of a Muse Cell-Based Product in Neonatal Hypoxic-Ischemic Encephalopathy with Therapeutic Hypothermia (SHIELD Trial).” Stem Cells Translational Medicine, vol. 13, no. 11, Nov. 2024, pp. 1053–66. EBSCOhost, https://doi.org/10.1093/stcltm/szae071.

APA

Sato, Y., Shimizu, S., Ueda, K., Suzuki, T., Suzuki, S., Miura, R., Ando, M., Tsuda, K., Iwata, O., Muramatsu, Y., Kidokoro, H., Hirakawa, A., Hayakawa, M., & team, the S. (2024). Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial). Stem Cells Translational Medicine, 13(11), 1053–1066. https://doi.org/10.1093/stcltm/szae071

Chicago

Sato, Yoshiaki, Shinobu Shimizu, Kazuto Ueda, Toshihiko Suzuki, Sakiko Suzuki, Ryosuke Miura, Masahiko Ando, et al. 2024. “Safety and Tolerability of a Muse Cell-Based Product in Neonatal Hypoxic-Ischemic Encephalopathy with Therapeutic Hypothermia (SHIELD Trial).” Stem Cells Translational Medicine 13 (11): 1053–66. doi:10.1093/stcltm/szae071.